#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Emphysema Ischaemic stroke Antithrombin III deficiency Pneumonia Chronic myeloid leukaemia Renal cell carcinoma Neonatal asphyxia Oropharyngeal cancer recurrent Marfan's syndrome Congenital hypotransferrinaemia Acute myeloid leukaemia (in remission) Aicardi-Goutieres syndrome Acute lymphocytic leukaemia Adenovirus infection Oesophageal squamous cell carcinoma stage III More trials…

    Learn about Rare Diseases

    Congenital generalised lipodystrophy – Trials in Disease Medulloblastoma recurrent Hereditary hypophosphataemic rickets Acute respiratory distress syndrome – Life with Disease Fabry’s disease – Life with Disease Turner’s syndrome – Basic Information Leiomyosarcoma – Basic Information Mantle cell lymphoma refractory – Trials in Disease Myelodysplastic syndrome – Life with Disease Alagille syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Alks 2680 Ergocalciferol Degarelix Cipepofol Pentixather MB-001 Fluticasone Radium Ra 223 Dichloride Amb-05X Linsitinib Vusolimogene Oderparepvec Forimtamig SIPAVIBART Allo-501A Bt8009 Zolbetuximab Erenumab M-(18F)-Fluorobenzylguanidine Oxybutynin HALOBETASOL PROPIONATE More therapies…

    Learn about Your Condition

    Open angle glaucoma Pancreatitis acute Malignant neoplasm of choroid Mental disorder Pancreatitis relapsing Neoplasm malignant Hypercholesterolaemia Dyslipidaemia Multifocal motor neuropathy Ocular hypertension Hypoxia Myxofibrosarcoma Raynaud's phenomenon Familial hypertriglyceridaemia Cervix carcinoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic lymphocytic leukaemia recurrent

  • Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • B-cell small lymphocytic lymphoma
    Investigated Drugs:
    • Venetoclax
    The Netherlands

  • Safety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Daratumumab
    • Obinutuzumab
    • Venetoclax
    Poland
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!